Inactive Instrument

Actelion Ltd Stock Swiss Exchange

Stocks

End-of-day quote Swiss Exchange
- ^CHF	-

17-07-31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
17-07-18	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE

17-07-31	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
17-07-18	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
17-07-18	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
17-06-09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
17-06-09	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
17-06-09	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
17-05-22	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
17-05-18	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
17-04-20	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
17-04-18	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
17-04-05	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
17-03-31	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
17-02-22	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

20-04-06	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
17-10-31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
17-06-30	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
17-06-16	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
17-06-15	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

18-01-29	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
18-01-29	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
18-01-22	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
17-10-31	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
17-10-30	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-2.11%	-3.44%	+41.04%	+98.48%	68.24B
ARGENX SE	-0.23%	-6.42%	+30.19%	+76.15%	62.23B
INSMED INCORPORATED	+1.67%	+2.16%	-11.32%	+392.80%	27.8B
WUXI BIOLOGICS (CAYMAN) INC.	-1.05%	-7.30%	+25.00%	+12.31%	24.86B
BIONTECH SE	+0.34%	-5.98%	-4.23%	-19.48%	24.22B
GENMAB A/S	+0.43%	-4.78%	+18.26%	-20.61%	19.36B
PHARMAESSENTIA CORPORATION	-3.03%	-5.19%	+192.88%	+340.13%	17.28B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.94%	-6.36%	-7.05%	+516.16%	14.46B
EXELIXIS, INC.	-2.28%	-5.09%	+48.86%	+153.82%	14.23B
Average	-0.91%	-3.96%	+37.07%	+172.20%	30.3B
Weighted average by Cap.	-0.86%	-3.80%	+33.61%	+136.95%